SunMax Biotechnology Co. Ltd.(TW:4728)
NT$388.000.00 (0.00%)
TW:4728
SunMax Biotechnology Co. Ltd. financials statements
NT$388.00
At close:0.00 (0.00%)
SunMax Biotechnology Co. Ltd. (4728) Ratios
SunMax Biotechnology Co. Ltd. Ratios
TW:4728's free cash flow for Q2 2026 was NT$265.36M. For the 2026 fiscal year, TW:4728's free cash flow was decreased by NT$-4.55M and operating cash flow was NT$269.91M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.89 | 3.09 | 2.36 | 2.78 | 2.36 |
| Quick Ratio | 3.37 | 2.43 | 2.15 | 2.55 | 2.19 |
| Cash Ratio | 2.42 | 1.27 | 1.87 | 1.81 | 1.80 |
| Solvency Ratio | 1.64 | 2.22 | 0.95 | 1.26 | 0.65 |
| Operating Cash Flow Ratio | 2.81 | 2.07 | 1.86 | 1.98 | 0.73 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 44151.78 | 167.37 | 88.96 | 24.61 |
| Net Current Asset Value | NT$ 637.49M | NT$ 255.80M | NT$ 345.95M | NT$ 437.58M | NT$ 327.13M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.03 | 0.08 | 0.04 | 0.07 |
| Debt-to-Equity Ratio | 0.07 | 0.04 | 0.12 | 0.05 | 0.11 |
| Debt-to-Capital Ratio | 0.07 | 0.04 | 0.11 | 0.05 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.31 | 1.22 | 1.51 | 1.35 | 1.45 |
| Debt Service Coverage Ratio | 166.21 | 438.02 | 87.55 | 69.03 | 23.94 |
| Interest Coverage Ratio | 204.40 | 641.05 | 304.15 | 578.20 | 129.24 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 2.28 | 1.13 | 3.16 | 1.32 | 2.05 |
| Net Debt to EBITDA | -0.54 | -0.20 | -0.70 | -0.62 | -1.19 |
| Profitability Margins | |||||
| Gross Profit Margin | 78.41% | 40.44% | 83.18% | 85.20% | 86.37% |
| EBIT Margin | 49.27% | 46.21% | 54.02% | 55.61% | 34.79% |
| EBITDA Margin | 54.32% | 50.12% | 58.33% | 59.74% | 40.14% |
| Operating Profit Margin | 49.27% | 50.99% | 52.98% | 55.55% | 35.01% |
| Pretax Profit Margin | 50.07% | 52.44% | 53.84% | 55.51% | 34.52% |
| Net Profit Margin | 35.82% | 37.37% | 37.05% | 38.13% | 23.72% |
| Continuous Operations Profit Margin | 35.82% | 37.37% | 37.05% | 38.13% | 23.72% |
| Net Income Per EBT | 71.53% | 71.27% | 68.81% | 68.69% | 68.71% |
| EBT Per EBIT | 101.63% | 102.84% | 101.63% | 99.94% | 98.58% |
| Return on Assets (ROA) | 34.18% | 36.71% | 28.98% | 29.77% | 16.55% |
| Return on Equity (ROE) | 44.86% | 44.91% | 43.88% | 40.28% | 24.00% |
| Return on Capital Employed (ROCE) | 54.56% | 55.89% | 52.59% | 53.00% | 31.53% |
| Return on Invested Capital (ROIC) | 38.50% | 39.69% | 35.57% | 35.90% | 20.90% |
| Return on Tangible Assets | 34.34% | 36.83% | 29.05% | 29.83% | 16.60% |
| Earnings Yield | 3.37% | 4.46% | 5.58% | 7.21% | 5.46% |
| Efficiency Ratios | |||||
| Receivables Turnover | 691.29 | 16.56 | 662.09 | 423.75 | 122.84 |
| Payables Turnover | 60.38 | 20.64 | 41.85 | 14.27 | 27.85 |
| Inventory Turnover | 2.87 | 2.99 | 3.03 | 2.81 | 2.58 |
| Fixed Asset Turnover | 2.20 | 2.15 | 2.15 | 1.86 | 1.85 |
| Asset Turnover | 0.95 | 0.98 | 0.78 | 0.78 | 0.70 |
| Working Capital Turnover Ratio | 3.24 | 3.55 | 2.81 | 2.71 | 1.84 |
| Cash Conversion Cycle | 121.84 | 126.30 | 112.17 | 105.23 | 131.36 |
| Days of Sales Outstanding | 0.53 | 22.05 | 0.55 | 0.86 | 2.97 |
| Days of Inventory Outstanding | 127.35 | 121.94 | 120.34 | 129.95 | 141.49 |
| Days of Payables Outstanding | 6.04 | 17.68 | 8.72 | 25.58 | 13.10 |
| Operating Cycle | 127.88 | 143.98 | 120.90 | 130.81 | 144.46 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 15.17 | 7.30 | 15.58 | 11.83 | 4.47 |
| Free Cash Flow Per Share | 13.91 | 6.62 | 13.55 | 8.99 | -0.22 |
| Dividend Paid and CapEx Coverage Ratio | 1.18 | 0.63 | 1.35 | 1.63 | 0.67 |
| Capital Expenditure Coverage Ratio | 12.09 | 10.85 | 7.69 | 4.15 | 0.95 |
| Operating Cash Flow Coverage Ratio | 6.92 | 6.59 | 5.02 | 9.16 | 2.23 |
| Operating Cash Flow to Sales Ratio | 0.41 | 0.22 | 0.50 | 0.46 | 0.23 |
| Free Cash Flow Yield | 3.51% | 2.37% | 6.58% | 6.61% | -0.27% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 29.71 | 22.45 | 17.93 | 13.88 | 18.31 |
| Price-to-Sales (P/S) Ratio | 10.64 | 8.39 | 6.64 | 5.29 | 4.34 |
| Price-to-Book (P/B) Ratio | 13.33 | 10.08 | 7.87 | 5.59 | 4.40 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 28.46 | 42.27 | 15.20 | 15.13 | -370.41 |
| Price-to-Operating Cash Flow Ratio | 26.10 | 38.38 | 13.22 | 11.49 | 18.49 |
| Price-to-Earnings Growth (PEG) Ratio | 4.31 | 2.63 | 1.04 | 0.12 | 5.72 |
| Enterprise Value Multiple | 19.05 | 16.54 | 10.69 | 8.24 | 9.63 |
| Enterprise Value | 20.97B | 15.07B | 10.53B | 6.89B | 4.01B |
| EV to EBITDA | 19.05 | 16.54 | 10.69 | 8.24 | 9.63 |
| EV to Sales | 10.35 | 8.29 | 6.24 | 4.92 | 3.87 |
| EV to Free Cash Flow | 27.68 | 41.76 | 14.27 | 14.07 | -329.78 |
| EV to Operating Cash Flow | 25.39 | 37.92 | 12.41 | 10.69 | 16.46 |
| Tangible Book Value Per Share | 29.53 | 27.67 | 26.09 | 24.26 | 18.72 |
| Shareholders’ Equity Per Share | 29.71 | 27.78 | 26.18 | 24.33 | 18.79 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.28 | 0.29 | 0.31 | 0.31 | 0.31 |
| Revenue Per Share | 37.21 | 33.38 | 31.01 | 25.71 | 19.02 |
| Net Income Per Share | 13.33 | 12.47 | 11.49 | 9.80 | 4.51 |
| Tax Burden | 0.72 | 0.71 | 0.69 | 0.69 | 0.69 |
| Interest Burden | 1.02 | 1.13 | 1.00 | 1.00 | 0.99 |
| Research & Development to Revenue | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 |
| SG&A to Revenue | 0.27 | 0.09 | 0.28 | 0.29 | 0.48 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.81 | 0.47 | 0.93 | 0.83 | 0.68 |
Currency in TWD
